Then, somewhere between eighteen and thirty-six months later, a regional MSL delivers a discussion aid that quietly contradicts pillar three, and the entire edifice wobbles. I have watched this exact sequence play out — in large pharma, in mid-size biotech, in organizations that genuinely cared about getting it right. The problem was never the concept; the problem was the rollout. We tend to treat SCPs like deliverables, when they are, in fact, operating systems.
That distinction matters because the numbers around SCP maturity are quietly damning. Medical Communications and Publications teams lead platform development in roughly 71% of pharmaceutical companies surveyed by Best Practices, LLC — yet only 36% of Mid-Small Pharma firms actually track how that content filters into the reactive and proactive pieces their field medical teams carry into the clinic. In Large Pharma, that figure climbs to 88%. We have built the cathedral; we have just not always installed the doors.
An SCP is not a slide template. It is the operating system your scientific narrative runs on — and an operating system that no one logs into is just shelfware with a logo.
The Strategic Architecture: What an SCP Actually Is
Let me strip the consultancy varnish off this. A Scientific Communication Platform is a layered narrative framework, not a document. Its job is to align disease state, mechanism of action, efficacy, safety, and value messaging across every function that touches scientific exchange — medical, commercial, market access, HEOR, and the field. When it works, an MSL in Munich, a medical writer in Boston, and a payer-engagement lead in Basel are all drawing from the same well, using the same language. When it does not work, you get the optical nightmare of two slides, two narratives, one launch.
The architecture that has become the de facto industry standard stacks five layers deep. At the top sit the Strategic Pillars — usually three to five — which represent the high-order scientific themes the product will own over its lifecycle. Underneath each pillar sit Strategic Objectives that translate the pillar into something a stakeholder can actually act on. Below the objectives sit the Core Scientific Statements: the load-bearing claims of the narrative, written with enough precision that they can be defended in an advisory board, a payer meeting, or a peer-reviewed publication. Below those sit the Evidence Statements, each one tethered to a specific piece of literature, trial readout, or real-world dataset. And underpinning the whole stack is the Lexicon — the controlled vocabulary that decides what the disease is called, how the mechanism is described, which efficacy endpoints earn the headline, and how safety language is calibrated.
I have seen organizations try to collapse the stack into a single "messaging matrix." It does not work. The moment you flatten the architecture, you lose the ability to trace a claim back to an evidence anchor — and traceability is what separates a scientific platform from a marketing pamphlet. Medical Affairs exists, in part, because someone has to hold that line.
Timing the Rollout: Why Late Phase II Is the Industry Benchmark
There is a persistent myth inside Medical Affairs — and I have heard it from CMOs, from heads of Medical, from people who should know better — that the SCP should be built after the Phase III data lands. The logic sounds reasonable: wait for the data, then build the narrative. The logic is also wrong, and the cost of getting it wrong is not theoretical.
The industry benchmark, drawn from Best Practices research and reinforced by how leading organizations actually sequence their work, places initial SCP development in the late stages of Phase II clinical trials. Not because the Phase II data is the story — it usually is not — but because the SCP is what shapes Phase III. The platform defines which endpoints matter, which subpopulations the narrative will defend, which safety questions the field will need to anticipate, and which gaps in the evidence base will need investigator-initiated trials to fill. Build it after Phase III reads out, and you are reverse-engineering a strategy from a dataset; you are not running one.
The practical implication is uncomfortable: by the time most organizations finish arguing about who owns the SCP, the window for shaping Phase III has already closed. I have sat in those arguments. They are not pretty. They are also entirely avoidable. Late Phase II gives you the runway — long enough to align Clinical Development, Commercial, Market Access, and the field medical organization on the pillars, the objectives, and the lexicon, before the Phase III topline makes the narrative concrete. Miss that window, and you spend the next three years apologizing to MSLs for the inconsistencies they have to navigate in the field.
Late Phase II is not a suggestion. It is the last clean moment to shape the narrative before the data — and the optics — lock you in.
Leadership and Governance: Who Actually Owns This
Let me address something the consultancies will not tell you plainly: the SCP almost never belongs to Commercial. The instinct to hand it over is real, and it is wrong. Medical Communications and Publications teams lead development in roughly 71% of pharmaceutical organizations surveyed. The reason is structural. SCPs are non-promotional scientific frameworks; their job is to anchor scientific exchange, not to drive demand. The moment a commercial director gets edit authority on a Core Scientific Statement, the statement stops being scientific and starts being an assertion with a literature citation stapled to it.
What does good governance look like? In the companies I have watched get this right, it looks like a Medical-led core team with explicit sign-off authority, supported by a cross-functional advisory layer that includes Clinical Development, Regulatory, Market Access, HEOR, and a rotating commercial representative whose job is to flag alignment gaps — not to rewrite the science. The platform gets reviewed on a fixed cadence (every six months is the rhythm I have seen work), with an explicit change-control process for any modification to a Core Scientific Statement. Modifications get logged. Rationale get documented. Statements do not drift.
The governance failure mode I have watched most often is the "consensus by committee" trap. Everyone gets a voice; no one gets accountability. The result is an SCP that reads like a Wikipedia entry on the product — technically accurate, strategically empty. Worse, when the field cannot figure out which pillar to lead with in a given stakeholder conversation, they default to whatever the most recent advisory board reinforced, and the platform calcifies into something it was never meant to be.
From Static Decks to Modular Digital Assets
The format question is where most organizations get stuck somewhere around 2014. Roughly 52% of biopharmaceutical companies still deliver their SCPs as PowerPoint decks, and another 24% favor interactive PDFs. I have nothing against either format — I have built both, and they have their place — but a deck is a presentation tool, not a content management system. Once you have fifty MSLs across four regions pulling slides out of a shared deck, you have fifty-one versions of the narrative, and the platform is no longer a platform.
The shift I am watching — slowly, unevenly, and not nearly fast enough — is toward modular digital platforms. Veeva Vault MedComms is the obvious example: SCPs configured as discrete objects — Communication Platforms, Pillars, Objectives, Scientific Statements (Primary, Secondary, Aspirational), and Statement Assets for the non-text visual content like mechanism animations and Kaplan-Meier graphics. The advantage is not aesthetic; it is governance. A modular object can be version-controlled, access-controlled, and tracked. A slide in a shared drive cannot.
For a sense of the operational scale: healthcare communications consultancy OPEN Health reported delivering 87 SCPs across its biopharmaceutical client base in 2024. That is not a vanity figure — it is a signal that SCP work has become a volume business, which means governance discipline, not authoring talent, is the differentiator.
Here is how the format decision tends to play out in practice:
| Format | Strength | Failure Mode | Best Fit |
|---|---|---|---|
| PowerPoint deck (52% of companies) | Fast to produce; familiar authoring environment | Drifts across copies; no usage telemetry; no version control | Early-stage SCPs; small field teams; pre-launch alignment work |
| Interactive PDF (24% of companies) | Portable; easier to annotate; better visual fidelity than deck | Still a static object; hyperlinks rot; analytics are shallow | Cross-functional review cycles; advisory board pre-reads; external scientific exchange |
| Modular cloud platform (growing segment) | Object-level version control; usage analytics; single source of truth | Implementation overhead; requires content governance the org may not yet have | Mature field medical organizations; Large Pharma; products with global launches and long lifecycle horizons |
The format is downstream of the strategy — but only just. If you are a Mid-Small Pharma firm with three MSLs and a single indication, a well-governed deck is a defensible answer. If you are running a global launch with forty-plus field medical team members across ten markets, a deck is a liability dressed up as a deliverable.
Measuring Impact: The 61% Problem
This is the section where most SCP programs quietly fall apart, and it is the one I have the strongest feelings about. Roughly 61% of pharmaceutical companies track how SCP content gets incorporated into the reactive and proactive materials their field medical teams use. In Large Pharma, that figure is 88%. In Mid-Small Pharma, it is 36%.
Read that last number again. It means nearly two-thirds of smaller organizations are building an SCP, handing it to the field, and never measuring whether it actually shows up in the conversations MSLs have with investigators, payers, and key opinion leaders. They are running an editorial exercise and calling it a strategic one.
What gets measured, in the organizations that do this well, is not vanity. It is not "did we produce the SCP." It is the harder, more useful set of questions: which Core Scientific Statements are appearing in reactive medical information responses; which Evidence Statements are MSLs citing in KOL engagements; where is the platform being under-deployed, and what does that tell us about the field's confidence in the narrative; which Statement Assets — the mechanism animation, the forest plot, the subpopulation breakdown — are actually being opened and shared.
I have watched teams discover, through this kind of tracking, that their "pillar one" was effectively absent from field exchange because the field did not understand how to position it against competitor narratives. That is not a field execution problem; it is an SCP design problem, and you cannot find it without the telemetry. Without the measurement layer, the SCP becomes a document the field respects in principle and ignores in practice — and respect without usage is just expensive shelfware.
The Rollout That Actually Works
So here is the takeaway, stripped of consultancy deck language: an SCP is not a project. It is a system, and systems require three things the industry routinely underinvests in.
1. Timing. Late Phase II is not a benchmark for the timid; it is the operational reality. The platform has to exist before Phase III shapes the data, or the platform ends up rationalizing a strategy someone else already chose.
2. Ownership. Medical Communications and Publications lead this in the majority of organizations for reasons that are not bureaucratic; they are structural. Hand it to Commercial and the science gets laundered into marketing.
3. Measurement. If you cannot tell me which Scientific Statements are reaching which stakeholders in which conversations, you do not have a Scientific Communication Platform. You have a deliverable.
The companies that get this right are not the ones with the best decks. They are the ones who treat the SCP the way a software company treats its platform: versioned, governed, measured, and evolved. Everyone else is just shipping slides into the echo chamber and calling it alignment.